CRH

Biomarker

Also known as: CRh

Related News

Kyowa Kirin and Kura start Japanese Phase II ziftomenib trial in relapsed or refractory AML

Apr 27, 2026

Kyowa Kirin and Kura Oncology started a Japanese Phase II registrational study of ziftomenib in adults with relapsed or refractory NPM1-mutated AML. Kyowa Kirin plans to seek regulatory approval in Japan after the trial.

Moleculin Reports 40% Response Rate in Pivotal AML Trial, Unblinding Expected Q1 2026

Feb 18, 2026

Moleculin Biotech announced a preliminary blinded composite complete remission rate of 40% in the first 30 subjects of its Phase 2B/3 MIRACLE trial testing Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia.